Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMMT05U)

Drug Name
GOSSYPETIN Drug Info
Synonyms
Gossypetin; Articulatidin; Equisporol; 489-35-0; 3,5,7,8,3',4'-Hexahydroxyflavone; UNII-SET4M23ZTM; 3,3',4',5,7,8-Hexahydroxyflavone; SET4M23ZTM; 2-(3,4-Dihydroxyphenyl)-3,5,7,8-tetrahydroxy-4H-chromen-4-one; CHEMBL253570; 2-(3,4-Dihydroxyphenyl)-3,5,7,8-tetrahydroxychromen-4-one; CHEBI:16400; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxy-; 2-(3,4-dihydroxyphenyl)-3,5,7,8-tetrahydroxy-chromen-4-one; PubChem9855; AC1NQXCW; BSPBio_002552; SPECTRUM1505143; SCHEMBL157033; BDBM26655; DTXSID50197631
Cross-matching ID
PubChem CID
5280647
ChEBI ID
CHEMBL253570
CAS Number
CAS 489-35-0
TTD Drug ID
D0Z7EL

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.37 0.00e+0 34/36 (94.44%) RPA3;MCM3;POLE2;...
Ribosome biogenesis in eukaryotes 2.36 0.00e+0 52/108 (48.15%) DKC1;IMP4;GNL3;...
Fanconi anemia pathway 2.26 0.00e+0 36/54 (66.67%) RPA3;RAD51;BRCA1;...
Homologous recombination 2.24 0.00e+0 35/41 (85.37%) RPA3;RAD51;BRCA1;...
Base excision repair 2.15 0.00e+0 29/33 (87.88%) POLE2;APEX1;FEN1;...
Cell cycle 1.99 1.79e-3 110/124 (88.71%) PLK1;SMC1A;CCNA2;...
Mismatch repair 1.91 2.30e-3 22/23 (95.65%) RPA3;RFC3;MSH2;...
Pyrimidine metabolism 1.84 7.36e-3 40/56 (71.43%) DCTPP1;CAD;NME1;...
RNA transport 1.84 6.55e-3 128/186 (68.82%) TACC3;XPO1;PRMT5;...
RNA polymerase 1.84 5.89e-3 23/31 (74.19%) POLR2I;POLR2H;POLR3G;...
Proteasome 1.80 6.82e-3 44/46 (95.65%) PSMD2;PSMA6;PSME3;...
Aminoacyl-tRNA biosynthesis 1.76 9.37e-3 15/66 (22.73%) GATC;NARS2;FARSA;...
Oocyte meiosis 1.66 2.22e-2 90/129 (69.77%) PLK1;SMC1A;AURKA;...
Ribosome 1.61 3.56e-2 113/158 (71.52%) MRPL3;MRPS12;MRPL20;...
Spliceosome 1.60 3.82e-2 101/150 (67.33%) SRSF1;SRSF7;SNRPD3;...
Nucleotide excision repair 1.58 4.52e-2 40/47 (85.11%) RPA3;POLE2;RFC3;...
Apoptosis -1.74 1.24e-2 126/168 (75%) FASLG;MAP2K2;CSF2RB;...
Asthma -1.74 1.28e-2 25/31 (80.65%) MS4A2;HLA-DMB;IL5;...
Rheumatoid arthritis -1.76 1.28e-2 78/93 (83.87%) CSF2;CD86;HLA-DOB;...
Amoebiasis -1.76 1.32e-2 99/102 (97.06%) COL4A1;FN1;PLCB4;...
NOD-like receptor signaling pathway -1.77 1.22e-2 145/181 (80.11%) MAPK14;TNF;CXCL3;...
Kaposi sarcoma-associated herpesvirus infection -1.78 1.15e-2 172/193 (89.12%) CSF2;PTGS2;HLA-C;...
Estrogen signaling pathway -1.79 1.20e-2 119/137 (86.86%) NCOA2;ADCY9;MAP2K2;...
Steroid hormone biosynthesis -1.79 1.14e-2 43/61 (70.49%) CYP11B1;UGT2B4;HSD3B2;...
Natural killer cell mediated cytotoxicity -1.79 1.19e-2 99/131 (75.57%) SH2D1A;MAPK1;LCP2;...
Bile secretion -1.81 1.05e-2 68/90 (75.56%) ABCB4;SLC27A5;AQP4;...
Porphyrin and chlorophyll metabolism -1.82 1.03e-2 23/43 (53.49%) BLVRA;ALAS2;UGT2B28;...
Fluid shear stress and atherosclerosis -1.85 6.51e-3 123/139 (88.49%) MAP3K5;PLAT;HSP90AA1;...
Allograft rejection -1.87 5.34e-3 32/38 (84.21%) HLA-DMB;HLA-E;FASLG;...
Retinol metabolism -1.87 5.66e-3 41/68 (60.29%) CYP2C18;CYP2B6;DHRS9;...
Legionellosis -1.89 4.29e-3 51/57 (89.47%) CLK4;TNF;CXCL3;...
ABC transporters -1.89 3.67e-3 37/45 (82.22%) TAP2;ABCC5;ABCA8;...
Histidine metabolism -1.92 3.93e-3 16/22 (72.73%) MAOA;HDC;ALDH3B1;...
Graft-versus-host disease -1.93 4.23e-3 32/42 (76.19%) HLA-DMB;KLRD1;HLA-E;...
Lipid and atherosclerosis -1.94 3.44e-3 190/215 (88.37%) FASLG;PLCB4;PLCB3;...
Ferroptosis -1.95 3.75e-3 36/41 (87.8%) FTL;SLC11A2;ACSL4;...
Lysosome -1.98 1.37e-3 115/128 (89.84%) LITAF;CLTA;GLA;...
Autophagy -1.99 1.53e-3 113/169 (66.86%) ITPR1;TRAF6;MAPK9;...
Mitophagy -2.00 1.72e-3 56/68 (82.35%) PINK1;UBC;BNIP3;...
Other glycan degradation -2.00 1.96e-3 13/18 (72.22%) ENGASE;HEXA;MANBA;...
Complement and coagulation cascades -2.01 2.29e-3 76/85 (89.41%) MASP2;CFI;PROC;...
Metabolism of xenobiotics by cytochrome P450 -2.04 2.75e-3 49/77 (63.64%) HSD11B1;CYP2A13;CYP2E1;...
IL-17 signaling pathway -2.15 0.00e+0 84/94 (89.36%) MAPK6;IL5;CSF2;...
Antigen processing and presentation -2.17 0.00e+0 60/78 (76.92%) HLA-E;CALR;NFYC;...
Staphylococcus aureus infection -2.21 0.00e+0 72/95 (75.79%) MASP2;KRT10;CFI;...
Protein processing in endoplasmic reticulum -2.46 0.00e+0 127/171 (74.27%) DERL2;SEC23B;CALR;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.2uM - 25uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.2uM - 25uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H